Short answer: no peptide has been shown to improve focus or memory in healthy adults. Cerebrolysin has by far the most human randomized-trial data, but Cochrane grades that evidence very low quality and warns any benefit may be too small to be clinically meaningful. Selank has one small human trial and it studied anxiety, not focus. Semax and Dihexa are essentially animal-only for cognition.
Research-use-only educational overview. This article is not medical advice and is not a recommendation to use, take, or buy any compound.
Search “best peptides for cognitive function and focus” and you will find confident rankings and shopping lists. This page takes a different approach. Instead of naming a “winner,” it looks at the three peptides people most often research and discuss in this context — Semax, Selank and Dihexa — and asks a harder question: what does the published evidence actually show?
One distinction runs through everything below. “Most studied” or “most discussed” is not the same as “proven to work,” and neither is the same as “right for you.” For scale, GLP-1 receptor agonists have large, replicated human randomized controlled trials behind their effects on body weight. The cognitive peptides here are nowhere near that standard — their evidence ranges from small human studies to animal-only data. Nothing on this page is a directive to use any compound. All three are sold for research use only, none is an approved treatment for cognition or focus, and this is educational information, not medical advice.
Comparison at a glance
| Peptide | What it’s studied for (re: cognitive function & focus) | Evidence tier | Key caveat |
|---|---|---|---|
| Semax | Neuroprotection and recovery after ischemic stroke; neurotrophin/BDNF modulation; popularly described as a “nootropic” | Preclinical (animal) plus limited, low-quality human use in Russia; no rigorous Western RCTs | Human cognitive-enhancement data in healthy people is essentially absent; evidence base is largely Russian-language |
| Selank | Anxiety reduction (which can indirectly affect attention); memory/attention in animal models | One small human RCT for anxiety; cognitive/focus effects preclinical or indirect | The human trial targeted anxiety, not focus; sold as an unregulated “supplement,” safety poorly characterized |
| Dihexa | Synapse formation and memory-task performance in animal models via the HGF/c-Met system | Preclinical (animal) only | No human trials; a foundational mechanistic paper was later retracted |
| Cerebrolysin | Cognitive and global function in Alzheimer’s disease and vascular dementia | Multiple human randomized controlled trials plus two meta-analyses — the most human data on this page | Cochrane grades the evidence very low quality; benefits may be too small to matter clinically, and disclosed funding was industry-supported |
Semax
Semax is a synthetic peptide based on a fragment of adrenocorticotropic hormone (ACTH 4–7) joined to a Pro-Gly-Pro tail. In Russia it is registered and used clinically as a neuroprotective agent for ischemic stroke and is popularly marketed as a “nootropic.” According to PubMed, the English-language research is dominated by animal models: in rat models of cerebral ischemia, Semax modulates neurotrophin signaling and dampens inflammatory and cell-death pathways (Sudarkina et al., 2021; Stavchansky et al., 2022). What is largely missing is rigorous, peer-reviewed human evidence — particularly placebo-controlled trials of cognition or focus in healthy adults. The honest read is that Semax is mechanistically interesting but that cognitive-enhancement claims in healthy people are not established. You can review the figures discussed in the research community on our Semax dosage reference.
Selank
Selank is a synthetic analog of the immune peptide tuftsin, developed in Russia primarily as an anxiolytic. It has the most direct human data of the three: a Russian comparative randomized trial in 62 patients with generalized anxiety disorder and neurasthenia reported anxiolytic effects comparable to the benzodiazepine medazepam, alongside mild anti-asthenic and stimulating effects (Zozulia et al., 2008). Crucially, that trial studied anxiety, not focus or memory — any effect on concentration would be indirect (less anxiety can make attention easier). Direct cognitive effects have mainly appeared in animals, for example rats in which Selank blunted alcohol-related memory and attention impairment while modulating BDNF (Kolik et al., 2019). A clinical-pharmacology review also cautions that Selank is poorly studied and is sold to US consumers as an unregulated “dietary supplement” (Doyno & White, 2021). Our Selank dosage reference documents how it is typically handled in research settings.
Dihexa
Dihexa is a small-molecule angiotensin IV analog engineered to cross the blood–brain barrier and promote synapse formation. In animal studies it has been reported to improve performance on memory tasks and to drive synaptogenesis through the hepatocyte growth factor (HGF)/c-Met system (Wright et al., 2015, review). This is the least human-validated compound on the page: there are no published clinical trials of dihexa itself for cognition, and — importantly for honesty — a key 2014 paper underpinning its procognitive mechanism was subsequently retracted (Benoist et al., 2014, later retracted). So while its laboratory potency looks striking, dihexa remains preclinical and its safety in humans is essentially uncharacterized. Our Dihexa dosage reference lists the numbers cited in the research literature, for documentation only.
Cerebrolysin
Cerebrolysin is the outlier here, and it is usually missing from “best peptides for focus” lists. It is a porcine brain-derived peptide preparation given as intravenous infusions, and unlike the other three it has been tested in genuine randomized controlled trials in people with cognitive impairment. A meta-analysis of six double-blind placebo-controlled trials in mild-to-moderate Alzheimer’s disease found a significant benefit on cognitive function at 4 weeks and on global clinical change at 4 weeks and 6 months, with safety comparable to placebo (Gauthier et al., 2015). A separate randomized trial found Cerebrolysin roughly as effective as donepezil in mild-to-moderate Alzheimer’s disease, with the combination scoring best (Alvarez et al., 2011).
Now the counterweight, and it matters. The 2019 Cochrane review of Cerebrolysin in vascular dementia pooled six trials and 597 participants, found a benefit on cognition and on global function, and then graded that evidence very low quality across every outcome — citing heterogeneity, high risk of bias, and the fact that every included trial with disclosed funding was industry-supported. Its conclusion was that if benefits exist the effects may be too small to be clinically meaningful, and that adequately powered, methodologically robust trials are still needed (Cui et al., 2019). Note also who was studied: people with diagnosed dementia, not healthy adults chasing sharper focus. Nothing in this literature speaks to the second use. Our Cerebrolysin dosage reference documents how it is handled in research settings.
What the evidence actually supports
Ranked by strength of human evidence rather than by hype:
- Cerebrolysin has the most human randomized-trial data by a wide margin — but it was tested in Alzheimer’s disease and vascular dementia, the evidence is graded very low quality, and the effect size may be too small to matter clinically.
- Selank has the most direct human data among the classic “nootropic peptides” — but for anxiety, not focus. Its attention and memory benefits remain preclinical or indirect.
- Semax has real-world clinical use in Russia and a substantial mechanistic literature, yet almost no rigorous, English-language human trials for cognition in healthy people.
- Dihexa is animal-only, carries a retraction in its foundational mechanistic work, and has no human trials.
The bottom line for “cognitive function and focus” specifically: none of the three has robust, replicated human randomized-controlled-trial evidence of enhancement in healthy adults. Anyone presenting a clear “best” is going beyond what the data supports. The strongest evidence here is for a neighboring outcome (anxiety), and the flashiest mechanistic story (Dihexa) is also the least validated in people.
Side effects and what is actually known about safety
- Cerebrolysin. Across the pooled trials, adverse-event rates did not differ from placebo, and the one trial that tracked mortality reported no deaths — but this comes from the same very-low-quality evidence base (Cui et al., 2019).
- Selank. The comparative trial reported anxiolytic effects similar to medazepam with mild stimulating effects; a clinical-pharmacology review cautions that Selank is poorly studied and is sold to US consumers as an unregulated “dietary supplement” (Doyno & White, 2021).
- Semax. Decades of clinical use in Russia have not produced rigorous published safety data in healthy adults outside that setting.
- Dihexa. No human safety data of any kind. Its profile in people is uncharacterized.
- Sourcing. Research-chemical supply is not held to pharmaceutical manufacturing standards, so purity and identity are risks separate from the molecule.
Important limitations
- Research use only. Semax, Selank and Dihexa are not approved by the FDA as treatments for cognition or focus, and are not approved cognitive-enhancement therapies anywhere in mainstream regulatory use.
- The evidence is thin. Much of it is animal data or small, older, non-English human studies, and one key dihexa paper was retracted — a reason for caution, not confidence.
- Individual results and safety are unknown. Purity, long-term safety, dosing, and interactions are poorly characterized, and unregulated “supplement” sourcing adds further risk.
- This is not medical advice. Decisions about your health belong with a qualified healthcare professional who knows your history.
If you are studying reconstitution and concentration math for research documentation, our peptide dosage calculator can help you check the numbers. It is an educational tool, not a prescription or an endorsement of use.
FAQ
Which peptide is “best” for focus?
No peptide has been proven “best” for focus in healthy people. Selank has the most direct human evidence, but it was studied for anxiety rather than focus, while Semax and Dihexa are largely preclinical for cognition. “Most studied” is not the same as “proven for you.”
Are these approved or safe for cognitive enhancement?
No. None is an approved cognitive-enhancement therapy, and all are sold for research use only. Their long-term safety in humans is not well characterized, and at least one is commonly sold as an unregulated supplement. Speak with a qualified healthcare professional before making any health decision.
Does animal or mechanistic evidence mean it works in people?
Not on its own. Many compounds that improve memory in rodents show no benefit in human trials, and mechanistic findings can later be overturned — as the retracted dihexa paper illustrates. Animal and mechanistic data are a reason for further study, not proof of a human effect.
Which of these has the most human evidence?
Cerebrolysin, by a wide margin — multiple randomized placebo-controlled trials and two meta-analyses. But those trials enrolled people with Alzheimer’s disease or vascular dementia, Cochrane graded the evidence very low quality, and the reviewers noted the effect may be too small to be clinically meaningful.
Do any of these work for focus in a healthy person?
No trial has tested that. Every human study discussed here enrolled patients — with anxiety, dementia or stroke — not healthy adults seeking sharper concentration. Extending a patient result to a healthy person is an assumption, not a finding.
What side effects have been reported?
Cerebrolysin’s pooled trials showed adverse-event rates no different from placebo. Selank’s comparative trial reported mild stimulating effects. Semax has little published safety data in healthy adults, and Dihexa has none in humans at all.
Educational, research-use-only information. Not medical advice, not a diagnosis, and not a recommendation to use any compound. Consult a qualified healthcare professional.
